Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00876941 · ClinicalTrials.gov registry record · Phase 3

Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use

A Phase 3 study of Drug Abuse and Drug Dependence, sponsored by Boston Medical Center.

Completed
Registry status
Phase 3
Development phase
589
Enrollment target
1
Study location

NCT00876941 is a Phase 3 study of Drug Abuse and Drug Dependence that has completed, run by Boston Medical Center. The registered enrollment target is 589 participants, above the 298-participant average among 21 other Drug Abuse trials with a reported enrollment target (98% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00876941, a Phase 3 study of Drug Abuse and Drug Dependence, has completed, sponsored by Boston Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
589 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to test whether screening and brief intervention for drug use among primary care patients leads to improved drug-related outcomes (such as decreased drug use and consequences).

Interventions

  • BEHAVIORAL Standard Brief Intervention
  • BEHAVIORAL Enhanced Brief Intervention
  • BEHAVIORAL Control: Information and Feedback

Study Locations (1)

Massachusetts

  • Boston Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 589 participants
Start Date 2009-04
Est. Completion 2014-09
Phase Phase 3

Sponsor

Boston Medical Center

253 total trials

What the Registry Record Tells You About NCT00876941

The ClinicalTrials.gov registry entry for NCT00876941 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 589 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 298-participant average among 21 other Drug Abuse trials with a reported enrollment target (98% higher). The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Drug Abuse appearing as the primary indexed condition, and to 3 interventions - of which Standard Brief Intervention is the first listed.

NCT00876941 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00876941 about?

NCT00876941 is a clinical study titled "Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use". The objective of this study is to test whether screening and brief intervention for drug use among primary care patients leads to improved drug-related outcomes (such as decreased drug use and consequences).

What is the current status of trial NCT00876941?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 589 participants. The study started on 2009-04. Estimated completion is 2014-09.

What conditions does trial NCT00876941 study?

This clinical trial studies the following conditions: Drug Abuse, Drug Dependence, Drug Usage.

What interventions are being tested in trial NCT00876941?

The interventions under investigation include: Standard Brief Intervention (BEHAVIORAL), Enhanced Brief Intervention (BEHAVIORAL), Control: Information and Feedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT00876941?

This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00876941 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Drug Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.